Allarity Therapeutics Inc. (NASDAQ: ALLR) announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for its patent application covering the stenoparib DRP companion diagnostic test.

The patent is expected to be formally granted within three months, subject to standard administrative procedures. The company stated the patent would provide exclusivity until at least 2039 for stenoparib when used with the DRP test as a companion diagnostic.

The allowed claims include methods for predicting clinical benefit based on gene expression profiles from tumor samples and for selecting patients most likely to benefit from stenoparib treatment.

"This Notice of Allowance from the USPTO represents another successful milestone in our efforts to secure intellectual property protection for our DRP technology in the US," said Thomas Jensen, CEO of Allarity Therapeutics.

Allarity previously secured European and Australian patents for the Stenoparib DRP and holds 18 granted patents for other drug-specific DRPs, including eight in the United States. Patent applications for the Stenoparib DRP remain pending in Canada, Japan, China, and India.

Stenoparib is an oral dual-targeted inhibitor of PARP1/2 and tankyrase 1/2 that the company is developing for cancer treatment. Allarity has exclusive global rights for stenoparib development and commercialization. The drug was originally developed by Eisai Co. Ltd.

The company operates two Phase 2 trials for stenoparib in ovarian cancer patients and one Phase 2 trial evaluating stenoparib combined with temozolomide for relapsed small cell lung cancer across multiple U.S. Veterans Administration sites.

The DRP platform uses gene expression signatures to select patients who may benefit from specific drugs. According to the company, the platform has demonstrated statistical significance in predicting clinical outcomes across multiple clinical studies.